Concurrent Chemoradiotherapy +/- Metformin HCL in NSCLC

To determine whether metformin hydrochloride (MET) added to chemoradiotherapy can improve progression-free survival (PFS) at 12 months in patients with locally advanced non-small cell lung cancer (NSCLC).

January 19, 2016